Skip to contentB
Bio-Rad Laboratories, Inc.
B
BIOBio-Rad Laboratories, Inc. Q2 2020 · 10-Q
Revenue$536.88M$536.88M−6.2% vs Q2 2019 Net Income$966.40M$966.40M+61.4% vs Q2 2019 EPS Diluted$32.15$32.15+61.9% vs Q2 2019 Gross Profit$293,000,000−4.8% Operating Income
The same fiscal quarter, prior years. Thaler holds no estimates to compare against.
Bio-Rad Laboratories, Inc. · CIK 12208 · Engraved from SEC EDGAR
Operating Cash Flowderived$92,122,000−40.7% Free Cash Flowderived$74,006,000−44.4% Margins · derivedGross margin54.6%+0.8 pt vs Q2 2019
Operating margin9.6%−0.2 pt vs Q2 2019
Net margin180.0%+75.4 pt vs Q2 2019
ended Jun 30, 2020 · filed Jul 31, 2020 · 31 d after period end